Refining the postmenopausal breast cancer treatment paradigm: The FACE trial

Expert Review of Anticancer Therapy

Volumn 6, Issue 10, 2006, Pages 1355-1359

  Monnier, Alain ^a  

^a Centre Hospitalier Belfort Montbéliard   (France)

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; FACE; Letrozole

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; NONHUMAN; POSTMENOPAUSE; PROGNOSIS; RECURRENCE RISK;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; MULTICENTER STUDIES; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; TRIAZOLES;

EID: 33750687260     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.10.1355     Document Type: Article

References (26)

1. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report. J. Clin. Oncol. 23, 619-629 (2004).
2. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 16, 1569-1583 (2005).
3. Rieber AG, Theriault RL. Aromatase inhibitors in postmenopausal breast cancer patients. J. Natl Compr. Cancer Netw. 3, 309-314 (2005).
4. Thürlimann B, Keshaviah A, Coates AS et al. for the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005).
5. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002). Erratum in: Lancet 360, 1520 (2002).
6. Howell A, Cuzick J, Baum M et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
7. Anastrozole (Arimidex) package insert. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (2005).
8. Buzdar AU, on behalf of the ATAC Trialists' Group. Impact of adjuvant chemotherapy prior to endocrine therapy: 68 month results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. Proc. Am. Soc. Clin. Oncol. 23, 30S (Abstract 608) (2005).
9. Dowsett M, Cuzick J, Wale C et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. 23, 7512-7517 (2005).
10. Viale G, Regan M, Dell'Orto P et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res. Treat. 94(Suppl. 1), S13 (2005) (Abstract 44).
11. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97, 1262-1271 (2005).
12. Eiermann W, Paepke S, Appfelstaedt J et al, Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12, 1527-1532 (2001).
13. Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative 'Arimidex' Compared to Tamoxifen (PROACT) trial. Cancer 106, 2095-2103 (2006).
14. Smith IE, Dowsett M, Ebbs SR et al. IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23, 5108-5116 (2005).
15. Mouridsen H, Gershanovich M, Sun Y et al, A Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21, 2101-2109 (2003).
16. Bonneterre J, Buzdar A, Nabholz JM et al. Arimidex Writing Committee; Investigators Commitee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92, 2247-2258 (2001).
17. Rose C, Vtoraya O, Pluzanska A et al. An open randomized trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer 39, 2318-2327 (2003).
18. Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr. Relat. Cancer 6, 187-195 (1999).
19. Bhatnagar AS, Brodie AM, Long BJ, Evans DB, Miller WR. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J. Steroid Biochem Mol. Biol. 76, 199-202 (2001).
20. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 20, 751-757 (2002).
21. Geisler J, Helle H, Ekse D et al. Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting. Proc. Am. Soc. Clin. Oncol. 24, 570S (2006) (Abstract 10532).
22. Dixon M, Renshaw L, Young O et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. Proc. Am. Soc. Clin. Oncol. 24, 15S (2006) (Abstract 552).
23. Mauriac LA, Keshaviah M, Debled H et al. Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial. Eur. J. Cancer Suppl. 4, 111 (2006).
24. +) breast cancer on tamoxifen. Proceedings of the 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, A3001 (2006).
25. Early Breast Cancer Trialists' Collaborative Group (FBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365, 1687-1717 (2005).
26. De Boer R, Burris H, Monnier A et al., on behalf of the H2H trial steering committee. The head to head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. Proc. Am. Soc. Clin. Oncol. 24, 582S (2006) (Abstract 10672).